US Penny Stocks To Watch In December 2024

In This Article:

As November 2024 comes to a close, the U.S. stock market is celebrating record highs with the S&P 500 and Dow Jones Industrial Average posting their biggest monthly gains of the year. For investors willing to explore beyond large-cap stocks, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities. Despite being considered a relic by some, these stocks can still provide significant potential when backed by strong financials, making them an interesting area for those seeking hidden value in under-the-radar companies.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.80

$5.81M

★★★★★★

Inter & Co (NasdaqGS:INTR)

$4.62

$2.03B

★★★★☆☆

QuantaSing Group (NasdaqGM:QSG)

$3.08

$136.98M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

ZTEST Electronics (OTCPK:ZTST.F)

$0.2408

$8.86M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.59

$52.47M

★★★★★★

PHX Minerals (NYSE:PHX)

$3.81

$142.8M

★★★★★☆

Zynerba Pharmaceuticals (NasdaqCM:ZYNE)

$1.30

$65.6M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.9429

$84.8M

★★★★★☆

Safe Bulkers (NYSE:SB)

$3.87

$413.23M

★★★★☆☆

Click here to see the full list of 708 stocks from our US Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

MacroGenics

Simply Wall St Financial Health Rating: ★★★★★★

Overview: MacroGenics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing antibody-based therapeutics for cancer treatment in the United States with a market cap of $225.32 million.

Operations: The company's revenue of $141.33 million is derived from its efforts in developing and commercializing monoclonal antibody-based therapeutics.

Market Cap: $225.32M

MacroGenics has demonstrated significant revenue growth, reporting US$110.71 million for Q3 2024 compared to US$10.4 million the previous year, though it remains unprofitable with a net loss of US$51.55 million over nine months in 2024. The company is debt-free and maintains strong short-term assets exceeding liabilities, providing a cash runway of over three years based on current free cash flow. Despite leadership changes with CEO Scott Koenig stepping down in early 2025, MacroGenics continues advancing its antibody-based therapeutics portfolio, highlighted by promising Phase 2 study results for vobramitamab duocarmazine targeting prostate cancer.